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Abstract: Durable hematopoietic stem cell engraftment requires efficient homing to and seeding in the recipient bone marrow.
Dissection of cellular and molecular mechanisms by retrospective analysis of functional engraftment studies imposes severe
limitations on the understanding of the early stages of this process. We have established an experimental approach for in vivo
functional imaging of labeled cells at the level of recipient bone marrow in real time.  The adhesive interaction of hematopoietic
cells with the bone marrow stroma evolves as the most important early event.  Adhesion to the marrow, rather than the vascular
endothelium, determines the efficiency of both homing and seeding, and is absolutely essential to maintain cell viability in the
marrow.  Seeding and engraftment may be improved either by bypassing homing or by localized transplant of a large number
of cells in a relatively small marrow space.  There is functional redundancy in the molecular pathways that mediate the
cell-stroma interaction, such that blockage of a single pathway has only minor effect on homing and seeding.  We hypothesize
that successfully seeding-engrafting cells undergo extensive phenotypic changes as a consequence of interaction with the
stroma, without engaging in rapid proliferation.  Surprisingly, Fas-ligand appears to promote hematopoietic cell engraftment
by immunomodulatory and trophic effects.
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Obligatory adhesion of transplanted cells to the
marrow stroma
Following transplant, hematopoietic stem cells infused
into the systemic circulation distribute in accordance
with hydrostatic and chemotactic determinants.  The
cells respond to chemotactic gradients generated by
local endothelia, adhere, roll and penetrate into the tissue
by means of trans-endothelial migration [21].  Homing
of hematopoietic stem and progenitor cells (HSPC) by
extravasation into the marrow space is considered to be
a pivotal process, because this is the only site that hosts
durable and multilineage differentiation of HSPC in nor-
mal conditions. Homing has caught much attention be-
cause of the phenomenal capacity of cells to respond to
chemotactic signals and successfully connect to their
"natural" site of residence [reviewed in 12, 16, 18, 21, 24].
One of the intriguing aspects of HSPC homing is its
temporality, over a period of many hours, in both synge-
neic and allogenenic transplant settings. Detectable le-
vels of labeled cells may be found in the peripheral blood
of recipients 6-9 and 3-6 hours after bolus injection of
syngeneic and allogeneic cells, respectively. The dif-
ference is somewhat expected due to the anticipated
entrapment of allogeneic cells in the host reticuloen-
dothelial system. Theoretically, the prolonged periph-
eral circulation of injected HSPC may be explained
either by failure of the cells to recognize the chemo-
tactic stimuli and adhere to the endothelium, or by a
bidirectional dynamic entry into and exit from the
marrow space.  Using intravital microscopy of the
femoral marrow, fluorochrome-labeled cells appear
and disappear within the marrow space in the hours
following intravenous injection [4], suggesting the
contention that homing and mobilization are indeed
similar processes in opposite directions [26]. This
leads us to believe that those cells that possess the
mechanisms to enter the marrow space can use the
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same molecular route to exit this space (mobilization↔
homing↔seeding).  
The rate limiting determinant of homing is in fact the
adhesive interaction with the stroma.  By 3 days after
intravenous injection, only ~50% of the cells that home
to the marrow establish stromal adhesion (seeding) [3].
The fate of non-adherent cells is death by apoptosis,
because interaction with the stroma is required to
preserve viability (Fig. 1).  At this early stage post-trans-
plantation, the loss of marrow-homed cells occurs in a
non-immunogenic manner, before alloimmunity is acti-
vated [6].  We have shown a strong relationship of
stromal-adherence and donor cell viability, though we
could not prove this relationship by simultaneous meas-
urements of adhesion and viability.  The mechanism of
clearance of the dead cells is unknown, though we
presume that a fraction of the dead cells leave the bone
marrow, while others are being cleared by phagocytic
cells that survived conditioning.  
A quantitative analysis of early engraftment revealed
an advantage in recognition of the bone marrow by more
primitive heamatopoietic progenitors, manifested by
differential homing and seeding efficiencies of lineage-
negative versus lineage-positive bone marrow cells.  As-
suming that homing is mediated by pre-existing
adhesion molecules expressed by the transplanted
HSPC, the affinity for the marrow stroma may be an
intrinsic property of bone marrow cells at various levels
of differentiation.  In general, 2-10% of the infused
lineage-negative cells home and seed in the marrow
stroma in vivo, more efficient by a factor of 20-30 than
lineage-positive cells [3, 4].  This process occurs physi-
ologically, with loss of stromal-adhesion during dif-
ferentiation in anticipation of release of matured cells
into the peripheral circulation.  However, selection of
marrow-repopulating cells by their repertoire of adhe-
sion molecules failed to accurately predict homing and
engraftability [20].  
It is likely that HSPC change their repertoire of
adhesion molecules during the first days post-transplan-
tation. In a fraction of ~20% of the transplanted cells that
are actively engaged in fast proliferation early after
transplantation [3], this process is associated with
phenotypic changes [22]. The majority of cells remains
mitotically-quiescent or is slow cycling, as evident by
the retention of cell surface fluorescent markers [3, 6].
The relatively quiescent state and slow cycling are asso-
ciated with engraftment potential, and are accompanied
by remarkable phenotypic changes [20, 22]. One
example is the induced expression of very late antigen-4
(VLA-4) in transplanted cells following interaction with
the marrow stroma [6]. Blockage of vascular cell adhe-
sion molecule-1 (VCAM-1) resulted in a more pro-
nounced decrease in seeding efficiency than inhibition
of VLA-4. We think that the robust effect of VCAM-1
inhibition on seeding is mediated by efficient expression
of VLA-4 following donor cell interaction with the
stroma.  
Functional redundancy of the adhesion molecules is
evident from failure of inhibition of a single ligand/re-
ceptor interaction to abolish seeding.  We believe that
selection of engraftable HSPC by the repertoire of adhe-
sion molecules that they express may be a conceptual
error.  Rather than selective seeding due to a single
pre-expressed molecule, as hypothesized to occur in the
case of homing, interaction with the marrow stroma is
accompanied by rapid phenotypic changes in cell sur-
face molecules.  In the in vivo experimental setting we
use marrow cellularity on days +1 and +3 post transplan-
tation to determine the homing and seeding efficiencies
of donor cells, respectively.  Anti-VLA4 blocking anti-
bodies reduced day +1 homing by a factor of 2, similar
to their effect on acute adhesion of bone marrow cells to
the stroma of femurs superfused ex vivo [6]. Because the
inhibitory effect was more pronounced on day +3 post-
transplantation (4.5-fold decrease), we assume that
VLA-4 plays a more important role as mediator of
seeding than of homing. In other words, the level of
functional redundancy for VLA-4 is higher at the level
of vascular endothelium than at the level of marrow
microenvironment. In parallel, seeded cells also showed
induced expression of putative stem cell markers includ-
ing SCA-1 and c-kit (NA, unpublished data). Our inter-
pretation of these data is that cells make use of the
pre-existing repertoire of adhesion molecules only for
the first steps of homing and early seeding. Soon there-
after, either synchronized by slow cycling or without
division, some HSPC express additional molecules, a
process that promotes engraftment.  
As observed in vivo, donor cell seeding and engraft-
ment in the host bone marrow is a highly organized
process, which repeats itself with remarkable precision.
According to the spatial and temporal patterns, we have
categorized seeding and engraftment into three levels
(Fig. 2). Donor bone marrow cells almost always adhere
to the stroma in proximity to each other, forming a
cluster of stem, progenitor and mature cells [9]. Primary
clusters are located at the endosteal surface of the murine
femoral epiphyses for the first 4-6 days post transplan-
tation [5, 9]. The transition to secondary clusters is
marked by a decrease in number of cells within the
clusters, and onset of proliferation of some cells while
others remain mitotically quiescent. We include in the
secondary clusters two types of niches, one that main-
tains functional quiescence and will continue to do so
for periods of many weeks, and a niche that promotes
early proliferation of progenitors [5]. The site of clo-
nogenic activity of HSPC shifts with time towards the
more central regions of the epiphyseal marrow and the
diaphyses, where tertiary niches host rapidly prolif-
erating cells. Rare observations suggest that the progeni-
tors crawl over the stromal surface towards the
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proliferation-supporting central regions of the marrow.
This temporo-spatial organization of seeding and early
engraftment illustrates the cooperativity of stromal regu-
lation and both, adaptive and intrinsic HSPC responsive-
ness in the dynamic of early engraftment.  
Localized engraftment
To dissociate between the homing and seeding, we have
compared (Fig. 3): (1) intravenous transplantation, (2)
intra bone-marrow injection, (3) isolated limb perfusion
and (4) ex vivo bone perfusion. The conceptual advant-
ages of directed HSPC injection into the bone marrow
or an isolated limb preparation are: (a) avoids donor cell
depletion by host immune system during circulation in
the peripheral blood, (b) eliminates the homing process,
(c) induces a mega-dose effect of hematopoietic stem
cell engraftment, and (d) improves the competitiveness
of donor cells for seeding niches.  
Isolated limb perfusion resulted in massive retention
of donor progenitors (as much as 68% of the blasts in
the femur of myeloablated hosts) corroborating the high
affinity of primitive hematopoietic cells for the bone
marrow [11]. With proximal occlusion of the femoral
artery and vein, there were very few (0.3%) labeled cells
Fig. 2. Temporo-spatial organization of seeding in femoral marrow.
Transition of cells to functionally-distinct niches is temporally and
spatially organized in time and space within the marrow.  Primary
seeding occurs in niches located at the endosteal surface of the
epiphyses that host clusters of stem, progenitor and mature cells for
4-5 days post-transplantation. Secondary seeding persists in the
marrow periphery, and includes two types of niches: those that will
host functionally- and mitotically-quiescent cells for long durations,
and those that host early dividing cells. Mature transplanted cells are
not present in the secondary niches. Differentiation and proliferation
occurs in parallel to migration to the tertiary seeding niche located
in the central marrow.  
Fig. 1. Obligatory cell interaction with the marrow stroma.  The
dominant factor in homing and seeding is interaction with the mar-
row stroma. This interaction is tightly correlated to the survival of
transplanted cells, and ~50% of the bone marrow-homed cells are
lost in the early stage of seeding.  A major cause of cell loss is failure
to adhere to the marrow stroma, a non-immunogenic mechanism that
culminates in cell death. On days 2-3 all marrow-residing donor cells
are adherent and viable.  
Fig. 3. Four approaches to study homing and seeding.  Intravenous
injection results in systemic dissipation of the cells and chemotaxis-
driven homing to the marrow.  In isolated limb perfusion prepara-
tions the cells still have to cross the endothelial barrier to enter the
marrow space, and with proximal occlusion of blood vessels the
transplant may be localized to one limb. Intra-bone marrow injection
introduces the cells directly into the bone marrow, eliminating both
homing and trans-endothelial migration. Intra-bone perfusion may
be performed in isolated bones ex vivo, to analyze the primary
cell-stroma interaction that does not involve de-novo expression of
adhesion molecules and cytokine receptors.  
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in the contralateral femur, as compared to ~9% observed
with intra-bone marrow injection and intravenous injec-
tion [11]. Intra-arterial injection without proximal vas-
cular occlusion is also an efficient approach to increase
the number of donor cells in the bone marrow, though it
did not result in detectably superior engraftment com-
pared to intravenous injection [13]. In all localized trans-
plants (intra-arterial, intra-bone marrow and isolated
limb perfusion), the superior donor cellularity in the
ipsilateral femur persisted for weeks, consistent with a
slow rate of bone-to-bone migration of HSPC [1, 7, 13,
17].  Progenitors mobilized from the infused to the con-
tralateral femurs showed immature phenotypes, but en-
gaged in proliferative activity at high rates [7],
supporting the ability of hematopoietic stem and pro-
genitor cells to perform stochastic clonogenic activity. 
Isolated limb perfusion resulted in comparable levels
of peripheral blood donor chimerism at 3-4 weeks as
compared to intravenous transplants, despite the smaller
size of donor inoculum by one order of magnitude. We
attributed this effect to a local "mega-dose" effect, cre-
ated by the relatively large number of cells infused into
a small marrow space [10]. Localized bone marrow
transplantation showed superior engraftment of T-cell-
depleted bone marrow cells and reduced incidence and
intensity of graft versus host disease [1, 17]. Thus the
first three conceptual advantages of localized transplants
were supported by the experimental findings. It is
unclear however, whether seeding is a competitive pro-
cess, where donor cells are to replace some of the host
cells in the bone marrow. Repeated injections of 105-108
cells both in vivo (NA, personal communication) and ex
vivo [2] resulted in progressive retention of cells, with-
out evident saturation of the marrow seeding niches.
Considering that we could load more than 8×106 lin- cells
in one femur (which comprises ~7% of the total murine
marrow space), for any practical purpose in the trans-
plant setting the availability of seeding niches is not a
limiting factor.  
Surprise: toxic molecules in disguise
The stem cell compartment in the bone marrow presents
surprising evidence of its responses to diverse physio-
logical stimuli.  A prominent example is the apparent
engraftment-supporting role of Fas-ligand, a molecule
that triggers apoptosis via interaction with its receptor
Fas. In studies using Fas-ligand to induce peripheral
tolerance in the bone marrow, an immune privileged site,
we and others observed a remarkable enhancement of
hematopoietic stem cell engraftment. One of the mech-
anisms of Fas-ligand is purely immunogenic, and in-
volves antigen-selective depletion of alloreactive
immune cells that would inhibit engraftment at the sys-
temic level and in the bone marrow [8].  However, an
additional trophic effect appears to support the activity
of engrafting cells per se.  Lentivirus-mediated infection
of hematopoietic stem and progenitor cells with Fas-li-
gand resulted in improved short term engraftment [25],
and addition of the soluble molecule to cultured cells
improved viability [14] and enhanced clonogenic activ-
ity [11]. This behavior was initially attributed to a low
expression of Fas by quiescent stem cells, rendering
them resistant to Fas-ligand-mediated apoptosis [19]
and the elevated expression of anti-apoptotic proteins in
HSPC [15]. We tested the effect of Fas-ligand in a
murine bone marrow transplant setting (Fig. 4). Al-
though the engineered chimeric Fas-ligand protein per-
sists for only 10 days in vivo [9], the short term superior
engraftment was sustained for a period consistent with
transition to durable engraftment.  This molecule also
blocked the modest decrease in levels of chimerism
usually observed during transition to long term engraft-
ment. This interesting phenomenon should be viewed in
perspective to the elevated expression of Fas in hemato-
poietic stem and progenitor cells after transplantation
[23], and the significant role of the Fas/Fas-ligand inter-
action as a mediator of allorejection [8]. It is yet un-
known whether the trophic effect of Fas-ligand is
mediated through Fas binding, and how it is distinguish-
able from the pro-apoptotic triggering pathway. 
Concluding remarks
Engraftment potential is determined by the ability of
hematopoietic progenitors to respond to the interaction
with bone marrow stroma by expression of cell surface
Fig. 4. Enhanced engraftment of bone marrow cells expressing
Fas-ligand protein in non-myeloablated hosts. An allotransplant
model of major and minor antigen-disparity, where recipients con-
ditioned with busulfan (LD25) were injected with unmanipulated
bone marrow cells (Naïive), cells expressing a non-functional (Con-
trol) and functional Fas-ligand protein. One third (Mix) or all of the
transplanted bone marrow cells (FasL) expressed a non-cleavable
recombinant Fas-ligand protein. The levels of donor chimerism were
assayed in the peripheral blood of hosts 3 and 12 weeks post-trans-
plantation.  *p<0.05 
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molecules accompanied by slow cycling or divisional
quiescence.  Because the mechanisms of HSPC-stroma
interaction are multiple, analysis of isolated pathways or
molecules may miss the multidimensionality of this
elegantly orchestrated process. In situ real time analysis
of seeding in live subjects is a promising technique that
will enhance our understanding of hematopoietic cell
engraftment.
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